Holen Sie sich die Stockscreener-App
2.89
3.34%
-0.10
Handel nachbörslich:
2.89
Schlusskurs vom Vortag:
$2.99
Offen:
$3
24-Stunden-Volumen:
671.84K
Relative Volume:
0.39
Marktkapitalisierung:
$329.59M
Einnahmen:
$618.00K
Nettoeinkommen (Verlust:
$-111.65M
KGV:
-2.0702
EPS:
-1.396
Netto-Cashflow:
$-107.53M
1W Leistung:
-0.69%
1M Leistung:
-15.25%
6M Leistung:
-23.75%
1J Leistung:
-24.74%
1-Tages-Spanne:
$2.83
$3.04
1-Wochen-Bereich:
$2.69
$3.04
52-Wochen-Spanne:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.89 | 321.61M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics Inc (CATX) Balance Sheet - TradingKey
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [²¹²Pb]VMT-α-NET in GEP-NETs - Quiver Quantitative
CATX|Perspective Therapeutics Inc|Price:2.820|Chg%:-0.090 - TradingKey
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Market Sentiment - Benzinga España
Perspective Therapeutics Inc (CATX) Cash Flow - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics, Inc. Revenue Breakdown – TRADEGATE:AAJ0 - TradingView
BTIG reiterates Perspective Therapeutics stock rating on manufacturing edge - Investing.com
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Dips 0.67% as Stock Hovers Near Support ZoneFair Value Gap - dars.gov.et
Perspective Therapeutics (CATX) gains 5.3% beneficial holder led by Millennium - Stock Titan
Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics (CATX) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics to present updated can... - Pluang
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 - The Manila Times
Perspective Therapeutics Announces ESMO 2026 Presentation of Updated [212Pb]VMT-α-NET Data in Advanced Neuroendocrine Tumors - Quiver Quantitative
Perspective's cancer-treatment data gets ESMO oral presentation Oct. 23 - Stock Titan
Is Perspective Therapeutics, Inc. (CATX) stock outpacing its medical peers this year? - MSN
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Perspective Therapeutics (CATX) Slides Over 5% as Support Levels Come into FocusOutside Reversal - dars.gov.et
CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times
Perspective Therapeutics (CATX) Barclays 27th Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr
Perspective Therapeutics (CATX) Proxy filing Summary - Quartr
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA) - The Globe and Mail
Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr
CATX Q1 2026 Earnings: Narrower Loss Beats Expectations as Pipeline Progress ContinuesRevenue Growth Report - dars.gov.et
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics (CATX) Surges 4.9% as Bullish Momentum Tests Key ResistanceBPI Bull Confirmed - DonanımHaber
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Perspective Therapeutics Inc-Aktie (CATX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Williamson Robert F III | Director |
Nov 12 '25 |
Buy |
2.10 |
9,498 |
19,946 |
9,864 |
1.04%
11.95%
Kapitalisierung:
|
Volumen (24h):